Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Toronto Research Chemicals ("TRC") is a leading Canadian life sciences company specializing in the manufacture and supply of complex organic small molecules—including analytical standards and stable isotope-labelled compounds—for biomedical researchers worldwide. Founded in 1982 by Dr. David Dime and now employing more than 450 staff across extensive laboratory facilities near Toronto/Vaughan Ontario, it offers a catalogue exceeding 350k unique chemical entities supporting pharmaceutical R&D across oncology, neurology infectious diseases/toxicology/environmental science/COVID‑19 diagnostics among others—but does not itself develop therapeutics or run clinical programs. In August 2019 it was acquired by UK-based measurement institute LGC Group’s Standards Division—a KKR portfolio company—and continues to expand its manufacturing footprint locally while serving customers globally from academic labs to major pharma companies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Toronto Research Chemicals.